Association of Immune-Related Adverse Events and the Efficacy of Anti-PD-(L)1 Monotherapy in Non-Small Cell Lung Cancer: Adjusting for Immortal-Time Bias
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose The association between immune-related adverse events (irAEs) and survival outcomes in non–small cell lung cancer (NSCLC) patients treated with programmed death-(ligand) 1 [PD-(L)1] inhibitors remains controversial, partly due to variations in dealing with immortal-time bias (ITB). Materials and Methods We retrospectively enrolled 425 advanced NSCLC patients who received anti–PD-(L)1 monotherapy between January 2016 and June 2021, stratifying them into irAE (n=127) and non-irAE (n=298) groups. The primary endpoint was to assess the impact of irAEs on progression-free survival (PFS) and overall survival (OS). Landmark (2-, 3-, 6-, and 9-month) and time-dependent Cox analyses were performed to eliminate ITB. Results With a median follow-up of 38.8 months, the occurrence of overall irAEs was significantly associated with superior PFS (11.2 vs. 3.4 months, p < 0.001) and OS (31.4 vs. 14.0 months, p < 0.001), which persisted in landmark and time-dependent Cox analyses. For the main organ-specific irAEs, skin, thyroid, and hepatic irAEs, respectively, showed significantly improved survival compared to the non-irAE group, whereas pneumonitis did not. Single-organ irAEs had the best outcomes compared with multi-organ or no irAE, which also held across subgroups of skin, thyroid, and hepatic irAEs. Moreover, severe grade irAEs and immunotherapy discontinuation had a detrimental effect on survival, systemic steroid therapy showed little effect, while immunotherapy resumption had tolerable safety and a trend of improved survival. Conclusion After adequately adjusting ITB, the occurrence of overall irAEs predicts for favorable efficacy of anti–PD-(L)1 monotherapy in NSCLC, with better outcomes observed in patients with skin, thyroid, or hepatic irAEs, particularly those with single-organ involvement.
Abstract
Purpose The association between immune-related adverse events (irAEs) and survival outcomes in non–small cell lung cancer (NSCLC) patients treated with programmed death-(ligand) 1 [PD-(L)1] inhibitors remains controversial, partly due to variations in dealing with immortal-time bias (ITB). Materials and Methods We retrospectively enrolled 425 advanced NSCLC patients who received anti–PD-(L)1 monotherapy between January 2016 and June 2021, stratifying them into irAE (n=127) and non-irAE (n=298) groups. The primary endpoint was to assess the impact of irAEs on progression-free survival (PFS) and overall survival (OS). Landmark (2-, 3-, 6-, and 9-month) and time-dependent Cox analyses were performed to eliminate ITB. Results With a median follow-up of 38.8 months, the occurrence of overall irAEs was significantly associated with superior PFS (11.2 vs. 3.4 months, p < 0.001) and OS (31.4 vs. 14.0 months, p < 0.001), which persisted in landmark and time-dependent Cox analyses. For the main organ-specific irAEs, skin, thyroid, and hepatic irAEs, respectively, showed significantly improved survival compared to the non-irAE group, whereas pneumonitis did not. Single-organ irAEs had the best outcomes compared with multi-organ or no irAE, which also held across subgroups of skin, thyroid, and hepatic irAEs. Moreover, severe grade irAEs and immunotherapy discontinuation had a detrimental effect on survival, systemic steroid therapy showed little effect, while immunotherapy resumption had tolerable safety and a trend of improved survival. Conclusion After adequately adjusting ITB, the occurrence of overall irAEs predicts for favorable efficacy of anti–PD-(L)1 monotherapy in NSCLC, with better outcomes observed in patients with skin, thyroid, or hepatic irAEs, particularly those with single-organ involvement.
참고문헌 (29)
- Berner F, "Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer", JAMA Oncol, 5, pp.1043~1047 (2019)
- Toi Y, "Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer", JAMA Oncol, 5, pp.376~383 (2019)
- de Moel EC, "Autoantibody development under treatment with immune-checkpoint inhibitors", Cancer Immunol Res, 7, pp.6~11 (2019)
- Postow MA, "Immune-related adver-se events associated with immune checkpoint blockade", N Engl J Med, 378, pp.158~168 (2018)
- Kang JH, "Predicting and preventing immune checkpoint inhibitor toxicity : targeting cytokines", Trends Immunol, 42, pp.293~311 (2021)
- Rogado J, "Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients", Eur J Cancer, 109, pp.21~27 (2019)
- Schweizer C, "Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1", PD-L1 inhibitors alone and in combination with radiotherapy, 2020, pp.140, 55~62
- Teraoka S, "Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab : a prospective cohort study", J Thorac Oncol, 12, pp.1798~1805 (2017)
- Giobbie-Hurder A, "Challenges of guarantee-time bias", J Clin Oncol, 31, pp.2963~2969 (2013)
- Maillet D, "Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors", Eur J Cancer, 132, pp.61~70 (2020)
- Haratani K, "Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer", JAMA Oncol, 4, pp.374~378 (2018)
- Sato K, "Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab", Lung Cancer, 115, pp.71~74 (2018)
- Fujimoto D, "Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer : a multicenter retrospective cohort study", Lung Cancer, 119, pp.14~20 (2018)
- Kfoury M, "Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias", Cancer Treat Rev, 110, pp.102452~ (2022)
- Socinski MA, "Association of immune-related adverse events with efficacy of atezolizumab in patients with non-small cell lung cancer : pooled analyses of the phase 3 IMpower130, IMpower132, and IMpower150 randomized clinical trials", JAMA Oncol, 9, pp.527~535 (2023)
- Osorio JC, "Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer", Ann Oncol, 28, pp.583~589 (2017)
- Shankar B, "Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer", JAMA Oncol, 6, pp.1952~1956 (2020)
- Lisberg A, "Treatment-related adverse events predict improved clinical outcome in NSCLC patients on KEYNOTE-001 at a single center", Cancer Immunol Res, 6, pp.288~294 (2018)
- Wang W, "The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors : a multicenter retrospective study", Cancer Immunol Immunother, 71, pp.1693~1703 (2022)
- Kurokawa K, "Association between the efficacy and immune-related adverse events of pembrolizumab and che-motherapy in non-small cell lung cancer patients : a retrospective study", BMC Cancer, 22, pp.1047~ (2022)
- Cheung YM, "Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors : a systematic review and meta-analysis", Cancer Immunol Immunother, 71, pp.1795~1812 (2022)
- Beaufils M, "Dysthyroidism during immune checkpoint inhibitors is associated with improved overall survival in adult cancers : data mining of 1385 electronic patient records", J Immunother Cancer, 11, pp.e006786~ (2023)
- Suresh K, "Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy", J Thorac Oncol, 14, pp.494~502 (2019)
- Naqash AR, "Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab : a pooled exploratory analysis from a global cohort", Cancer Immunol Immunother, 69, pp.1177~1187 (2020)
- Verheijden RJ, "Immunosuppression for immune-related adverse events during checkpoint inhibition : an intricate balance", NPJ Precis Oncol, 7, pp.41~ (2023)
- Esfahani K, "Moving towards personalized treatments of immune-related adverse events", Nat Rev Clin Oncol, 17, pp.504~515 (2020)
- Henderson Berg MH, "Potential therapies for immune-related adverse events associated with immune checkpoint inhibition : from monoclonal antibodies to kinase inhibition", J Immunother Cancer, 10, pp.e003551~ (2022)
- Simonaggio A, "Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer", JAMA Oncol, 5, pp.1310~1317 (2019)
- Santini FC, "Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC", Cancer Immunol Res, 6, pp.1093~1099 (2018)